The Oncology Institute Reports Tomorrow With Profitability Still More Promise Than Pattern

The Oncology Institute Inc (NASDAQ: TOI) reports first-quarter 2026 earnings after market close on Wednesday, May 7, 2026, with a conference call scheduled for 5:30 PM ET. The central question: can this value-based community oncology provider continue its recent momentum of narrowing losses and beating estimates? With analysts expecting -$0.07 per share and the stock trading at $3.80, investors will be watching closely to see if TOI can sustain the operational improvements that drove its Q4 2025 beat.

Part 1: Earnings Preview

The Oncology Institute operates as a pioneer in value-based community oncology care, delivering specialized cancer treatment through over 100 clinic locations across five states to approximately 1.9 million patients. The company generates revenue through three segments: Dispensary, Patient Services, and Clinical Trials & Other, offering in-house infusion, clinical trials, radiation, and comprehensive patient support services.

For Q1 2026 ending March 31, analysts expect TOI to report a loss of -$0.07 per share on revenue of approximately $143.35 million. The most recently reported quarter (Q4 2025) delivered -$0.06 per share, beating the consensus estimate of -$0.08 by $0.02. Year-over-year, the Q1 2026 estimate of -$0.07 represents significant improvement compared to Q1 2025's actual loss of -$0.18 per share, marking a +61.11% reduction in losses.

Three key themes define this earnings story:

Medicare Savings Performance: TOI achieved $1.8 million in Medicare savings during CMS Enhancing Oncology Model Performance Period 3, marking substantial period-over-period improvement. This demonstrates the company's ability to deliver value-based care while controlling costs—a critical metric for investors evaluating the sustainability of TOI's business model in an increasingly value-focused healthcare environment.

Revenue Growth Trajectory: With Q4 2025 revenue of $141.96 million beating estimates and full-year 2026 revenue projected at $647.84 million, investors are watching whether TOI can maintain its growth momentum. The company's expansion across five states and strategic collaboration with Healthly Forge in Southern California signal continued geographic and service line expansion.

Path to Profitability: Analysts have dramatically revised their full-year 2026 loss estimate from -$0.54 to -$0.20 per share over the past 90 days, reflecting growing confidence in TOI's operational improvements. The question is whether management can provide guidance showing a clear timeline to breakeven and positive cash flow.

Analyst commentary ahead of the release emphasizes TOI's improving operational efficiency and the scalability of its value-based care model. With four analysts maintaining buy-equivalent ratings and price targets ranging from $5.00 to $8.00, the Street sees substantial upside potential if the company can execute on its growth and margin expansion plans.

Part 2: Historical Earnings Performance

TOI has demonstrated improving execution over its last four reported quarters, with a notable shift in estimate-beating performance. In Q4 2025, the company reported -$0.06 per share versus the -$0.08 consensus, delivering a +25.00% beat—its strongest positive surprise in the available history. This marked a sharp reversal from Q3 2025's -$0.14 result (missing -$0.12 estimates by -16.67%) and Q2 2025's -$0.15 (missing -$0.14 by -7.14%).

The pattern reveals volatility in quarterly performance but a clear trend toward better-than-expected results in recent quarters. Q1 2025's -$0.18 had no estimate for comparison, but the subsequent three quarters showed TOI initially struggling to meet expectations before finding its footing in Q4. The magnitude of beats and misses has been relatively modest—ranging from 7% to 25%—suggesting the company is operating within a reasonably predictable range as its business model matures.

Looking at the trajectory, TOI has narrowed its losses substantially from -$0.18 in Q1 2025 to -$0.06 in Q4 2025, a 67% improvement over three quarters. This consistent sequential improvement, culminating in the Q4 beat, suggests the company's operational initiatives are gaining traction and sets a positive backdrop for the Q1 2026 report.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TOI typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

TOI exhibits high volatility around earnings releases, with an average absolute Day 0 move of 9.57% and Day +1 move of 16.34%. The Day +1 reaction is particularly pronounced, averaging 24.26% intraday range, indicating substantial post-earnings price discovery.

The directional pattern shows mixed but increasingly positive reactions in recent quarters. The most recent Q4 2025 report (March 2026) saw a modest 5.07% decline on Day 0 but rallied +8.40% on Day +1 following the earnings beat. Similarly, Q1 2025 (May 2025) dropped 10.57% on Day 0 but surged +28.27% on Day +1. The Q3 2025 report (November 2025) produced the most dramatic move: down 10.20% on Day 0, then up +28.90% on Day +1.

This pattern suggests the market tends to underestimate TOI's results in the anticipatory session, then reprices sharply higher once actual numbers are released—particularly when the company beats estimates. The 16.34% average Day +1 move indicates investors should expect significant price action following Wednesday's after-hours release, with historical precedent suggesting upside potential if TOI delivers another beat.

Part 2.2: Options Market Expected Move

The options market is pricing a 13.42% expected move through the May 15 expiration, implying a range of $3.29 to $4.31. This is below the stock's average historical Day +1 move of 16.34% and substantially below the 24.26% average Day +1 range, suggesting options may be underpricing potential volatility based on TOI's recent earnings history.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on TOI with an average rating of 4.40 out of 5.00, firmly in buy territory. The consensus includes 3 Strong Buy ratings, 1 Moderate Buy, and 1 Hold, with no sell recommendations. This reflects strong conviction in the company's value-based care model and growth trajectory.

The average price target of $7.00 implies 84% upside from the current price of $3.80, with estimates ranging from a low of $5.00 (+32% upside) to a high of $8.00 (+111% upside). This wide range reflects differing views on the timeline to profitability and the ultimate scalability of TOI's platform, but even the most conservative target suggests meaningful appreciation potential.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.40. This stability suggests analysts are waiting for the Q1 results to either confirm their bullish thesis or prompt revisions. The lack of recent downgrades despite the stock's recent volatility indicates confidence in the company's fundamental trajectory.

The consensus view centers on TOI's ability to leverage its value-based care infrastructure to drive margin expansion as revenue scales. With full-year 2026 loss estimates improving from -$0.54 to -$0.20 per share over the past 90 days, analysts see a clear path toward profitability, making the current valuation attractive relative to the growth opportunity.

Part 4: Technical Picture

The Barchart Technical Opinion shows TOI in a Buy signal at 40%, strengthening from 24% last week but down from a Sell signal at 24% last month. This recent improvement reflects positive momentum heading into earnings, though the signal remains relatively weak in absolute terms.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum and positive technical setup for the earnings release
• Medium-term (50% Sell): Moderate sell signal suggests some intermediate-term resistance or consolidation pressure that could cap gains
• Long-term (50% Buy): Moderate buy signal reflects a constructive longer-term trend despite recent volatility

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting the recent price strength lacks conviction and could be vulnerable to disappointment if earnings miss expectations.

TOI is trading at $3.80, positioned above most key moving averages: above the 10-day ($3.68), 20-day ($3.53), 50-day ($3.23), and 100-day ($3.24), but below the 5-day ($3.95) and 200-day ($3.45). This configuration shows the stock has built a technical base above intermediate support levels but has pulled back slightly from very recent highs.

The technical setup presents a mixed picture heading into earnings. The stock's position above most moving averages and the 100% short-term buy signal provide a supportive foundation, but the weak and weakening trend characteristics suggest limited margin for error. The 13.42% options-implied move appears conservative given historical volatility, potentially offering opportunity for options buyers if TOI delivers another beat and sustains the pattern of strong Day +1 rallies. Key resistance sits at the 5-day moving average of $3.95, while support is established at the 20-day of $3.53. A beat-and-raise scenario could propel the stock toward the $4.31 upper end of the expected range or beyond, while a miss could test the $3.29 lower bound or the 50-day support at $3.23.